Given the relatively novel discovery of MET exon 14-skipping mutations in LUAD, there is a lack of insight towards how the METΔex14 oncogene aberrantly engages its parallel downstream signaling pathways, especially compared to its role when amplified in other oncogene-driven cancers. Here, MET is linked to cancer.